The estimated Net Worth of Mark Pruzanski is at least $16.7 Milion dollars as of 31 December 2019. Mark Pruzanski owns over 100 units of Intercept Pharmaceuticals Inc stock worth over $8,915,294 and over the last 12 years he sold ICPT stock worth over $1,167,411. In addition, he makes $6,615,780 as President, Chief Executive Officer a Director at Intercept Pharmaceuticals Inc.
Mark has made over 41 trades of the Intercept Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 100 units of ICPT stock worth $2,150 on 31 December 2019.
The largest trade he's ever made was exercising 50,000 units of Intercept Pharmaceuticals Inc stock on 25 November 2019 worth over $633,000. On average, Mark trades about 6,496 units every 27 days since 2012. As of 31 December 2019 he still owns at least 469,226 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Mark Pruzanski stock trades at the bottom of the page.
Dr. Mark Pruzanski M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Prior to co-founding the Company, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co-author of a number of scientific publications and is named as an inventor on several of our patents. Dr. Pruzanski has been a director of Equillium, Inc. since September 2018. Dr. Pruzanski also currently serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree from McGill University in Montreal, Canada.
As the President, Chief Executive Officer a Director of Intercept Pharmaceuticals Inc, the total compensation of Mark Pruzanski at Intercept Pharmaceuticals Inc is $6,615,780. There are no executives at Intercept Pharmaceuticals Inc getting paid more.
Mark Pruzanski is 52, he's been the President, Chief Executive Officer a Director of Intercept Pharmaceuticals Inc since 2002. There are 11 older and 9 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Mark's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein a Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: